Drug search by name

Emtricitabine, rilpivirine, and tenofovir and Liver impairment

Result of checking the interaction of drug Emtricitabine, rilpivirine, and tenofovir and disease Liver impairment for safety when used together.

Check result:

Emtricitabine, rilpivirine, and tenofovir <> Liver impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Hepatic adverse events have been reported in patients taking rilpivirine. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations. A few cases of hepatic toxicity have been reported in patients with no pre-existing hepatic conditions or risk factors. Appropriate laboratory testing prior to treatment and monitoring for hepatotoxicity is recommended, especially in patients with hepatitis B or C or patients with marked elevations in transaminases. The use of rilpivirine has not been studied in patients with severe hepatic impairment (Child Pugh Class C).

Emtricitabine, rilpivirine, and tenofovir

Generic Name: emtricitabine / rilpivirine / tenofovir

Brand Name: Complera, Odefsey

Synonyms: Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate

What is Emtricitabine, rilpivirine, and tenofovir?